Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MOCRU and its partner Medical Action Myanmar (MAM) have begun a study to identify areas in Myanmar where Burkholderia pseudomallei is present in the soil and where people are at risk of melioidosis, a difficult to diagnose deadly bacterial disease.

Myanmar B. pseudomallei study kicks off

MOCRU Director Frank Smithuis is Principal Investigator for the study, which will take 2,000 samples from 200 locations across Myanmar and then look at hospitals where B. pseudomallei seems prevalent and see if it can confirm melioidosis in patients. The Dept of Medical research will do the microbiology for the study.

A highly pathogenic bacterium commonly found in soil and water in South and Southeast Asia and endemic in northeast Thailand and northern Australia, B. pseudomallei causes melioidosis. Contracted through the skin, lungs or by drinking contaminated water, melioidosis is difficult to diagnose as it mimics other diseases. B. pseudomallei is resistant to a wide range of antimicrobials, and a cause of sepsis with a high mortality rate (50-90% depending on level of care available).  

Although melioidosis was first described in Rangoon (Yangon) in 1912, the distribution of B. pseudomallei in soil and the extent of melioidosis in Myanmar remains largely unknown. Local studies have confirmed the presence of B. pseudomallei in soil and confirmed clinical cases of melioidosis in Yangon. Other melioidosis cases have been found on the Thai-Myanmar border.

Funded by MAM, the study will run for 6-12 months and contribute to the global mapping of B. pseudomallei.

A landmark 2016 study by MORU’s Direk Limmathurotsakul that predicted that melioidosis is likely to be present in many more countries than previously thought, estimated that there may have been up to 6,247 melioidosis cases resulting in 3,687 deaths in Myanmar in 2015.

-Text and photos courtesy of Frank Smithuis and Liz Ashley

Similar stories

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

World’s largest clinical trial for COVID-19 treatments expands internationally

EOCRU OCGHR OUCRU OUCRU-Nepal Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.